Laron Syndrome (LS), (OMIM# 262500), a rare recessively inherited disease caused by deletions or mutations of the GH receptor, gene characterized by
dwarfism with low or undetectable serum
IGF-I in the presence of high serum GH. In addition to
dwarfism, the
IGF-I deficiency leads to metabolic abnormalities including aberrations in protein biosynthesis and homeostasis. The only available treatment for LS patients is (r)
IGF-I administration. The present study was aimed to determine the plasma concentrations of specific
amino acids and their metabolites in the blood of untreated and
IGF-I-treated LS patients. The study involved a total of 10 LS patients (3 untreated and 7 treated), 2 heterozygote mothers and 3aged subjects. Forty healthy boys and girls served as controls. The analysis of
amino acids and their metabolites was performed using the LC-MS/MS analysis and Waters Acc-Q Tag ultra-derivatization kit. Serum
IGF-I levels were measured by a one-step sandwich chemiluminescence immunoassay. The results revealed that long-term
IGF-I deficiency in LS patients led to abnormal changes in the plasma
amino acids metabolism, such as low levels of plasma
citrulline,
sarcosine and
taurine that increased upon
IGF-I replacement. The plasma
amino acid levels of the heterozygous family members resembled those of the untreated LS patients, whereas the pattern in the 2 double heterozygote sisters previously treated with
IGF-I resembled that of the presently
IGF-I-treated patients. In addition, plasma ɑ-amino
adipic acid levels were elevated in both untreated and
IGF-I-treated patients. In summary our data revealed that LS patients, a condition associated with congenital
IGF-I deficiency, have an abnormal plasma
amino acid metabolism that is partially restored by
IGF-I treatment.